What investor type does Lilly (Eli) fit best in FoxScore?

Lilly (Eli) fits a more opportunity-seeking investor type in FoxScore: performance is the strongest sub-score. That suggests above-average historical returns — but check stability to ensure the performance wasn’t “paid for” with high volatility or deep drawdowns.

How meaningful is the available history for Lilly (Eli)?

Lilly (Eli) currently has about 15 years of price history available. That covers multiple market cycles including crisis phases, making long-term interpretation of returns, drawdowns and trend shifts more reliable.

What is FoxScore good for — and what is it not for?

FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.

Analysis for Lilly (Eli)

LLY · As of: 02/17/2026

Basic information

Type: Stock

Region: US

Sector: Health Care

TER: –

History

Available history:15.0 years

Last tradingday:02/17/2026

Description & usage

Eli Lilly develops and markets prescription medicines, with major areas including diabetes, obesity, oncology, and neuroscience. Revenue comes from drug sales to wholesalers, pharmacies, and healthcare systems. Customers are global, with a strong US market and growing international reach.

Scale: 0 = weak, 50 = average, 100 = top

Analysis summary

Lilly (Eli) (LLY) currently has a total score of 74 points, placing it in the strong range. The score is made up of Performance (92), Stability (54) and Trend (61). The profile is clearly uneven: Performance stands out while Stability is more neutral.

Performance scores 92 points (very strong). Key strength: 5Y return at 417.4 %. Even the weakest return is still strong in absolute terms: 1Y return at 19.7 %.

Stability scores 54 points (neutral). Key strength: CAGR/drawdown ratio at 0.87. Weaker metric: volatility (365d, annualized) at 41.7 %. That implies elevated swings. Higher Stability points are better and typically reflect calmer swings and smaller drawdowns—but prices can still fall.

Trend scores 61 points (strong). Key strength: Price is about 20.7 % above SMA200. Main drag: Price is about 0.7 % below SMA50.

Overall, the profile has a clear strength in Performance, while Stability is the main limiter. On a metric level, CAGR/drawdown ratio stands out, while volatility (365d, annualized) is the main weak spot.

(Historical evaluation, not investment advice.)

Chart anzeigen

Wenn du fortfährst, wird der Chart von TradingView geladen. Dabei können Daten (z. B. deine IP-Adresse) an TradingView übertragen werden.

Overall score

strong

Scores

Metrics

FAQ

What investor type does Lilly (Eli) fit best in FoxScore?: Lilly (Eli) fits a more opportunity-seeking investor type in FoxScore: performance is the strongest sub-score. That suggests above-average historical returns — but check stability to ensure the performance wasn’t “paid for” with high volatility or deep drawdowns.
How meaningful is the available history for Lilly (Eli)?: Lilly (Eli) currently has about 15 years of price history available. That covers multiple market cycles including crisis phases, making long-term interpretation of returns, drawdowns and trend shifts more reliable.
What is FoxScore good for — and what is it not for?: FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.